These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 10594467)
1. Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo. Larsen JT; Hansen LL; Brosen K Br J Clin Pharmacol; 1999 Nov; 48(5):663-8. PubMed ID: 10594467 [TBL] [Abstract][Full Text] [Related]
2. Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease. Fontana RJ; deVries TM; Woolf TF; Knapp MJ; Brown AS; Kaminsky LS; Tang BK; Foster NL; Brown RR; Watkins PB Br J Clin Pharmacol; 1998 Sep; 46(3):221-8. PubMed ID: 9764962 [TBL] [Abstract][Full Text] [Related]
3. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. Rasmussen BB; Brøsen K Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Matzke GR; Frye RF; Early JJ; Straka RJ; Carson SW Pharmacotherapy; 2000 Feb; 20(2):182-90. PubMed ID: 10678296 [TBL] [Abstract][Full Text] [Related]
5. Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo. Larsen JT; Brøsen K Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):141-8. PubMed ID: 16128907 [TBL] [Abstract][Full Text] [Related]
6. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577 [TBL] [Abstract][Full Text] [Related]
7. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Hägg S; Spigset O; Lakso HA; Dahlqvist R Eur J Clin Pharmacol; 2001 Sep; 57(6-7):493-7. PubMed ID: 11699614 [TBL] [Abstract][Full Text] [Related]
8. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827 [TBL] [Abstract][Full Text] [Related]
9. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Rasmussen BB; Brøsen K Ther Drug Monit; 1996 Jun; 18(3):254-62. PubMed ID: 8738764 [TBL] [Abstract][Full Text] [Related]
10. The major fluvoxamine metabolite in urine is formed by CYP2D6. Spigset O; Axelsson S; Norström A; Hägg S; Dahlqvist R Eur J Clin Pharmacol; 2001 Nov; 57(9):653-8. PubMed ID: 11791895 [TBL] [Abstract][Full Text] [Related]
11. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Damkier P; Brøsen K Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551 [TBL] [Abstract][Full Text] [Related]
12. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258 [TBL] [Abstract][Full Text] [Related]
13. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Fontana RJ; Turgeon DK; Woolf TF; Knapp MJ; Foster NL; Watkins PB Hepatology; 1996 Jun; 23(6):1429-35. PubMed ID: 8675160 [TBL] [Abstract][Full Text] [Related]
14. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Carrillo JA; Dahl ML; Svensson JO; Alm C; Rodríguez I; Bertilsson L Clin Pharmacol Ther; 1996 Aug; 60(2):183-90. PubMed ID: 8823236 [TBL] [Abstract][Full Text] [Related]
15. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. Zaigler M; Rietbrock S; Szymanski J; Dericks-Tan JS; Staib AH; Fuhr U Int J Clin Pharmacol Ther; 2000 May; 38(5):235-44. PubMed ID: 10839467 [TBL] [Abstract][Full Text] [Related]
16. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Becquemont L; Ragueneau I; Le Bot MA; Riche C; Funck-Brentano C; Jaillon P Clin Pharmacol Ther; 1997 Jun; 61(6):619-27. PubMed ID: 9209244 [TBL] [Abstract][Full Text] [Related]
17. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM J Clin Pharmacol; 1999 Mar; 39(3):252-9. PubMed ID: 10073324 [TBL] [Abstract][Full Text] [Related]
18. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity. Sinués B; Fanlo A; Bernal ML; Mayayo E; Soriano MA; Martínez-Ballarin E Ther Drug Monit; 2002 Dec; 24(6):715-21. PubMed ID: 12451287 [TBL] [Abstract][Full Text] [Related]
19. Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity. Terziivanov D; Bozhinova K; Dimitrova V; Atanasova I Clin Pharmacokinet; 2003; 42(15):1393-409. PubMed ID: 14674790 [TBL] [Abstract][Full Text] [Related]
20. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Härtter S; Ursing C; Morita S; Tybring G; von Bahr C; Christensen M; Röjdmark S; Bertilsson L Clin Pharmacol Ther; 2001 Jul; 70(1):10-6. PubMed ID: 11452239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]